Hepatic Artery Infusion With Oxaliplatin
Colorectal Cancer - Metastasis - Liver Cancer
Conditions: official terms
Colorectal Neoplasms
Conditions: Keywords
hepatic artery infusion, colorectal cancer, liver metastasis, oxaliplatin, 5 fluorouracil
Study Type
Study Phase
Phase 1/Phase 2
Study Design
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: Oxaliplatin (via HAI) Type: Drug
Name: 5 Fluorouracil (systemic) Type: Drug
Overall Status
Hepatic artery infusion (HAI) with oxaliplatin (OX), systemic 5 fluorouracil (5FU), and leucovorin (HAI/OX/FU) will be implemented using an interventional radiology technique to obviate the need for initial major surgery (catheter placement) in patients who have unresectable liver metastasis from colorectal cancer. The study goal is to reduce tumor size to make possible a complete resection of all lesions. Secondary goals are to reduce or eliminate the complexity usually associated with HAI, to accomplish most or all of the treatment as an outpatient, to reduce costs, and to avoid the hepatotoxicity associated with HAI/floxuridine (FUDR). Oxaliplatin has been selected because of its ease of use, known toxicology, and established efficacy in colorectal cancer.
Detailed Description
After entry qualification and registration patients will undergo hepatic artery catheterization via interventional radiology. The catheter will remain in place for two hours while oxaliplatin is infused and then be removed. This treatment will be followed by a 48 hour infusion of 5FU and leucovorin, generally following the principle of FOLFOX 6. These cycles of therapy will be repeated biweekly for six episodes. Hepatic tumor size will be evaluated by CT scan to determine if resectability has been established as the result of tumor size reduction. If so, the patient will be offered resection of the residual lesions in an effort to achieve long term survival.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

1. Signed consent

2. Age greater than 17 years

3. Stage IV colorectal cancer

4. Metastasis limited to the liver considered unresectable for cure by standard methods

5. Completely resected primary tumor

6. Life expectancy greater than 3 years excluding cancer

7. Eastern Cooperative Oncology Group (ECOG) status 0, 1, 2

8. Absolute granulocyte count greater than 1500

9. Platelet count greater than 100,000

10. Adequate hepatic function

11. Adequate renal function

Exclusion Criteria:

1. Concomitant anticancer therapy other than this protocol

2. Gastroduodenal ulcer

3. Pregnancy or lactation

4. Last treatment for colon cancer less than 4 weeks from this protocol
Medical College of Wisconsin/ Froedtert Hospital
Milwaukee, Wisconsin, United States
Status: Recruiting
Start Date
October 2005
Completion Date
December 2007
Medical College of Wisconsin
Medical College of Wisconsin
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page